57 results
PRE 14A
AKRO
Akero Therapeutics Inc
16 Apr 24
Preliminary proxy
4:30pm
is qualified to serve on our board of directors due to his significant experience in the healthcare and biotechnology industry.
Yuan Xu, Ph.D.
Dr. Xu has … in Healthcare Investment Banking at Citigroup Inc from May 2006 until September 2017. Previously, he served as an associate and later as a Vice
8-K
EX-1.1
AKRO
Akero Therapeutics Inc
6 Mar 24
Entry into a Material Definitive Agreement
5:25pm
healthcare programs; (iii) similar local, state, federal, national, supranational and foreign laws the directives and regulations promulgated pursuant
424B5
AKRO
Akero Therapeutics Inc
6 Mar 24
Prospectus supplement for primary offering
5:16pm
with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse, transparency and other healthcare laws … efforts;
sales of our common stock by us, our insiders or our other stockholders;
changes in the structure of healthcare payment systems;
general
424B5
44dmkb0du0t05agjl
4 Mar 24
Prospectus supplement for primary offering
5:21pm
8-K
EX-1.1
pz3o6
17 May 23
Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock
5:01pm
424B5
lctrc4i n9j
17 May 23
Prospectus supplement for primary offering
4:45pm
8-K
EX-1.1
lnhe25oiwb1g5y5a2
16 Sep 22
Entry into a Material Definitive Agreement
4:02pm
424B5
srj93140 n4
15 Sep 22
Prospectus supplement for primary offering
5:16pm
424B5
9wcrupyxc01e4y59jsfu
13 Sep 22
Prospectus supplement for primary offering
5:11pm
8-K
EX-10.1
lvvaa8 bqabdoh7cly
16 Jun 22
Akero Therapeutics Announces Two Financing Transactions with Pfizer Inc. and Hercules Capital, Inc. Providing Access to Up To $125 Million
7:14am